Oncology Venture is represented at the 4th Biotech & Money World Congress in London, 5-6th February.

Hørsholm, Denmark, 5th of February 2018 – Oncology Venture Sweden AB (OV:ST) reports from the 4th Biotech & Money World Congres. Oncology Venture have scheduled meetings with several companies on the 5-6th February. These companies are potential investors or biotech/pharma with interest in either in-licensing or co-development of oncology drugs or companies with drugs of interest to Oncology Venture for in-licensing. Further, OV will give a presentation of the company on the 6th February.

For further information, please contact:

Ulla Hald Buhl, COO och chef för IR & kommunikation                        Peter Buhl Jensen, VD

Telefon: +45 21 70 10 49                                                                         Telefon: +45 21 60 89 22

E-post: uhb@oncologyventure.com                                                      E-post: pbj@oncologyventure.com 

About Oncology Venture Sweden AB

Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction - DRP® - in order to significantly increase the probability of success in clinical trials. DRP® has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients' tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.

The current product portfolio: LiPlaCis® for Breast Cancer in collaboration with Cadila Pharmaceuticals, Irofulven developed from a fungus for prostate cancer and APO010 - an immuno-oncology product for Multiple Myeloma.

Oncology Venture has spun out two companies in Special Purpose Vehicles: 2X Oncology Inc. a US based company focusing on Precision medicine for women's cancers with a pipeline of three promising phase 2 product candidates. OV-SPV 2 is a Danish company that shall test and potentially develop an oral phase 2 Tyrosine Kinase inhibitor. Oncology Venture currently holds 92 percent of the shares in 2X Oncology Inc. and 40 percent of the shares in OV-SPV 2. 

Documents & Links